圣诺生物预计前三季度实现净利1.14亿元至1.4亿元，同比预增100.53%至145.1%

Core Viewpoint - Shengnuo Biotech (688117) expects a significant increase in net profit for the first three quarters of 2025, projecting a profit between 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.1% [1] Financial Performance - The company anticipates a net profit increase of 57.25 million to 82.63 million yuan compared to the same period last year [1] - The projected net profit for the first three quarters is between 114 million to 140 million yuan [1] Business Development - Shengnuo Biotech reports stable development in its main business, with continuous growth in demand for its peptide raw materials business [1] - The ongoing construction of production capacity is contributing to the sustained growth in orders, which in turn is driving overall performance improvement [1] - The company maintains strong market competitiveness and continuous profitability [1]